Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover which cash back credit card offers the best rates in 2023. Compare options to find the card that maximizes your benefits.
27,149 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Small, consistent savings can compound into meaningful retirement wealth. This article breaks down the math behind sa...
Pi Network pushes forward with key KYC milestones as the Core Team signals momentum in its comeback. Over 18 million ...
TIAA’s CEO argues that leaders should rent the title, not own it, and invest in character traits that endure beyond a...
On May 12, 2026, the U.S. welcomed its first spot ETF tied to Hyperliquid's HYPE token. THYP opened on NASDAQ with $1...
A prominent AI founder challenges the notion that automation alone boosts margins, revealing a doubled headcount desp...
Chipotle deployed Ava Cado, an AI chatbot, to handle candidate questions, collect basics, schedule interviews, and se...
A charged Tampa show reveals how public moments can ripple into personal finance choices. Learn practical budgeting t...
A single stock rally can expose ETF flaws. Learn how this chip ready micron moment reshapes EMG chip ETFs and what to...
Newly listed Roundhill DRAM ETF faces a volatile late-year backdrop as contract pricing and hyperscaler demand swing ...
A new AI-powered forecast tied to Grok AI projects XRP climbing to roughly $1.75-$1.80 within 28 days, if Bitcoin sta...
Ethereum appears to hold a clearer path for near-term traders, while Ripple’s XRP may deliver stronger gains for thos...